140 related articles for article (PubMed ID: 32239370)
21. Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma.
Liu Y; Yang H; Chen T; Luo Y; Xu Z; Li Y; Yang J
PLoS One; 2015; 10(5):e0127092. PubMed ID: 25978653
[TBL] [Abstract][Full Text] [Related]
22. CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations.
Guernet A; Mungamuri SK; Cartier D; Sachidanandam R; Jayaprakash A; Adriouch S; Vezain M; Charbonnier F; Rohkin G; Coutant S; Yao S; Ainani H; Alexandre D; Tournier I; Boyer O; Aaronson SA; Anouar Y; Grumolato L
Mol Cell; 2016 Aug; 63(3):526-38. PubMed ID: 27453044
[TBL] [Abstract][Full Text] [Related]
23. The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer.
Dong C; Chen Y; Li H; Yang Y; Zhang H; Ke K; Shi XN; Liu X; Li L; Ma J; Kung HF; Chen C; Lin MC
Int J Biol Sci; 2019; 15(7):1523-1532. PubMed ID: 31337981
[No Abstract] [Full Text] [Related]
24. CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer.
Ng SR; Rideout WM; Akama-Garren EH; Bhutkar A; Mercer KL; Schenkel JM; Bronson RT; Jacks T
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):513-521. PubMed ID: 31871154
[TBL] [Abstract][Full Text] [Related]
25. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.
Tang F; Min L; Seebacher NA; Li X; Zhou Y; Hornicek FJ; Wei Y; Tu C; Duan Z
J Orthop Res; 2019 Mar; 37(3):789-798. PubMed ID: 30667081
[TBL] [Abstract][Full Text] [Related]
26. Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
van der Wekken AJ; Kuiper JL; Saber A; Terpstra MM; Wei J; Hiltermann TJN; Thunnissen E; Heideman DAM; Timens W; Schuuring E; Kok K; Smit EF; van den Berg A; Groen HJM
PLoS One; 2017; 12(8):e0182885. PubMed ID: 28854272
[TBL] [Abstract][Full Text] [Related]
27. CRISPR/Cas9 treatment causes extended TP53-dependent cell cycle arrest in human cells.
Geisinger JM; Stearns T
Nucleic Acids Res; 2020 Sep; 48(16):9067-9081. PubMed ID: 32687165
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
29. Roles of TGFβ1 in the expression of phosphoinositide 3-kinase isoform genes and sensitivity and response of lung telocytes to PI3K inhibitors.
Song D; Tang L; Wang L; Huang J; Zeng T; Fang H; Wang X
Cell Biol Toxicol; 2020 Feb; 36(1):51-64. PubMed ID: 31522336
[TBL] [Abstract][Full Text] [Related]
30. Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells.
Kovacsics D; Brózik A; Tihanyi B; Matula Z; Borsy A; Mészáros N; Szabó E; Németh E; Fóthi Á; Zámbó B; Szüts D; Várady G; Orbán TI; Apáti Á; Sarkadi B
Biochem Pharmacol; 2020 May; 175():113865. PubMed ID: 32142727
[TBL] [Abstract][Full Text] [Related]
31. Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors.
Clement E; Inuzuka H; Nihira NT; Wei W; Toker A
Sci Signal; 2018 Mar; 11(521):. PubMed ID: 29535262
[TBL] [Abstract][Full Text] [Related]
32. Spindle Assembly Checkpoint Inhibition Can Resensitize p53-Null Stem Cells to Cancer Chemotherapy.
Liu C; Banister CE; Buckhaults PJ
Cancer Res; 2019 May; 79(9):2392-2403. PubMed ID: 30862715
[TBL] [Abstract][Full Text] [Related]
33. CRISPR-Cas9-based target validation for p53-reactivating model compounds.
Wanzel M; Vischedyk JB; Gittler MP; Gremke N; Seiz JR; Hefter M; Noack M; Savai R; Mernberger M; Charles JP; Schneikert J; Bretz AC; Nist A; Stiewe T
Nat Chem Biol; 2016 Jan; 12(1):22-8. PubMed ID: 26595461
[TBL] [Abstract][Full Text] [Related]
34. Neuropeptide gastrin-releasing peptide induces PI3K/reactive oxygen species-dependent migration in lung adenocarcinoma cells.
Jaeger N; Czepielewski RS; Bagatini M; Porto BN; Bonorino C
Tumour Biol; 2017 Mar; 39(3):1010428317694321. PubMed ID: 28351312
[TBL] [Abstract][Full Text] [Related]
35. Selective and potent small-molecule inhibitors of PI3Ks.
Jeong Y; Kwon D; Hong S
Future Med Chem; 2014 May; 6(7):737-56. PubMed ID: 24941870
[TBL] [Abstract][Full Text] [Related]
36. Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression.
Wang YC; Wu DW; Wu TC; Wang L; Chen CY; Lee H
Int J Biol Sci; 2018; 14(1):47-56. PubMed ID: 29483824
[TBL] [Abstract][Full Text] [Related]
37. A novel small-molecule PI3K/Akt signaling inhibitor, W934, exhibits potent antitumor efficacy in A549 non-small-cell lung cancer.
Wang J; Wang HY; Shen Y; Liang D; Wang HY; Zhang SQ; Cao YX; Cao L
Anticancer Drugs; 2019 Oct; 30(9):900-908. PubMed ID: 30913062
[TBL] [Abstract][Full Text] [Related]
38. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
[TBL] [Abstract][Full Text] [Related]
39. Carboxylated nanodiamond-mediated CRISPR-Cas9 delivery of human retinoschisis mutation into human iPSCs and mouse retina.
Yang TC; Chang CY; Yarmishyn AA; Mao YS; Yang YP; Wang ML; Hsu CC; Yang HY; Hwang DK; Chen SJ; Tsai ML; Lai YH; Tzeng Y; Chang CC; Chiou SH
Acta Biomater; 2020 Jan; 101():484-494. PubMed ID: 31672582
[TBL] [Abstract][Full Text] [Related]
40. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
